Viatris announces positive top-line results from phase 3 study of effexor® in japanese adults with generalized anxiety disorder (gad)

Treatment with once-daily effexor® met primary and all secondary efficacy endpoints in outpatient adults with gad effexor® was generally well tolerated, consistent with its known safety profile pharmaceuticals and medical devices agency (pmda) submission targeted for 2025 pittsburgh and tokyo , oct. 9, 2024 /prnewswire/ -- viatris inc. (nasdaq: vtrs), a global healthcare company, today announced positive top-line results of its phase 3 study (b2411367) in japan evaluating the safety and efficacy of effexor® (venlafaxine) in adults with generalized anxiety disorder (gad). the study achieved its primary objective of superiority of anxiolytic effects of venlafaxine compared to placebo at 8 weeks, based on the change in the hamilton anxiety rating scale (ham-a) total score from baseline (two-sided p-value=0.012).
VTRS Ratings Summary
VTRS Quant Ranking